COR
Specialty is the new engine
Cencora is basically telling investors: the pharmacy distribution business still matters, but the real juice is in specialty. Management said the company expects its specialty-first strategy to keep supporting growth into fiscal 2027, with demand in oncology and retina doing a lot of the work.
That matters because specialty drugs tend to be a better business than plain-vanilla distribution. They’re more complex, more service-heavy, and usually bring stickier customer relationships — which is corporate-speak for "less likely to vanish because somebody blinked." Cencora is also leaning on expanded physician-services capabilities, which suggests it wants more of the workflow, not just the delivery truck part.
Why investors should care
If Cencora can keep stacking growth on top of specialty care, that can help the company defend margins and keep the market interested in a fairly unglamorous sector. And in healthcare distribution, boring can be beautiful — especially when the boring part starts acting like a growth story.
The headline mention of Cardinal Health is more of a framing device than the point of the story. The real takeaway is that Cencora is signaling its specialty strategy still has runway, and that runway now stretches into fiscal 2027.
Big picture: this is the kind of update that won’t make your pulse race, but it can quietly matter a lot if you own the stock.